Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Encorafenib (BRAFTOVI™) to Treat Patients with BRAFV600E-Mutant Metastatic Colorectal Cancer (mCRC)
<p xss=removed>Encorafenib (BRAFTOVI™), in combination with binimetinib (MEKTOVI®) and cetuximab has been designed to treat patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).</p> <p xss=removed>BRAFV600E-mutant mCRC will be an important treatment option to the cancer patients in critical need.</p> <p xss=removed>The results were made from the safety lead-in of the ongoing randomised Phase 3 BEACON CRC trial showed that, at ...
Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Treats Relapsed/Refractory FLT3-ITD AML
<p xss=removed>Daiichi Sankyo Company, Limited announced quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD Acute Myeloid Leukemia (AML).</p> <p xss=removed>Quizartinib is the first FLT3 inhibitor to enhance overall survival as an oral, single agent compared to chemotherapy in patients with relapsed/refractory AML with FLT3-ITD, an underlying driver of this subtype of AML.</p> ...
Portola Pharmaceuticals Introduces Antidote for the Reversal of Factor Xa Inhibitors
<p xss=removed>Portola Pharmaceuticals develops Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.</p> <p xss=removed>Andexxa’s rapid reversal of the anticoagulating effects of rivaroxaban and apixaban will help clinicians treat life-threatening ble...
Amgen and Novartis Pharma Collaborate to Develop Novel Approach for Migraine Prevention
<p xss=removed>Amgen in collaboration with Novartis Pharma AG has developed Aimovig™, a novel therapeutic approach to prevent a migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in a migraine.</p> <p xss=removed>Aimovig 70 mg is self-administered once monthly via Amgen's device, the SureClick® autoinjector, and does not require a loading dose. Some patients may benefit fro...
World's First Metal-based Probes for Detection of Dopamine Receptors - Developed by HKBU Researchers
<p>A team of researchers of Hong Kong Baptist University has developed the world’s first metal-based probes for the identification of dopamine receptors in living cells. This breakthrough innovation helped the researchers to understand the dopamine receptors in carcinogenesis.<br> <br> Dopamine is an organic chemical of the catecholamine and phenethylamine which act as an important neurotransmitter in the central nervous system of a human body...
ChargePoint Technology launches VERIFI®- a Intelligent Monitoring Hub
<p xss=removed>ChargePoint Technology launches first-of-its-kind intelligent monitoring platform namely VERIFI which helps in tracking the most critical data of numerous valve installations. This will send alerts directly to H&S, maintenance and compliance teams to reduce unplanned maintenance downtime.</p> <p xss=removed>The VERIFI comprises an open/close handle which can be connected directly to ChargePoint valve for continuous recording of ...
First-of-its-kind Doptelet will soon be Available to Control Life-threatening Bleeding
<p xss=removed>Dova Pharmaceuticals announced that US Food and Drug Administration (FDA) has given green signal to Doptelet (avatrombopag) prescriptive medicine for the treatment of thrombocytopenia in adult patients affecting with a chronic liver disease.</p> <p xss=removed>Doptelet is used to treat low platelet counts in adults affecting with severe liver disease and who are scheduled to undergo a treatment.</p> <p xss=removed>With the he...
Roche Launches Hemlibra to Treat Haemophilia A without Factor VIII Inhibitors
<p>Roche launches Hemlibra for the treatment of people suffering from haemophilia A without factor VIII inhibitors.</p> <p>Hemlibra is a bispecific medicine which is injected under the patient’s skin in order to develop required proteins, activate the natural coagulation cascade and to restore the blood clotting process for people affecting with haemophilia A.</p> <p>This is a first-ever medicine to exhibit superior efficacy compared to fac...
Optical Sample Patent Approved for Breakthrough Cell Culture Management Technology
<p>The new breakthrough cell management technology now can be safe guarded with a patent right by all the Cell Culture Laboratories working with sensitive cell types.</p> <p>Under this protection, all the cell laboratories will be ensured for optimal sample security for gene therapy, cell therapy and regenerative medicine applications.</p> <p>Thermo Scientific Cell Locker system segregates the sensitive cells into separate protected chamber...
FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
<p xss=removed>The US Food and Drug Administration (FDA) grants Proteostasis Therapeutics' PTI-428, a Breakthrough therapy for the treatment of cystic fibrosis patients with two copies of the F508del genetic mutation who are receiving Orkambi® as background therapy.</p> <p xss=removed>PTI-428 is an investigational CFTR amplifier in the development for treating CF in patients who are homozygous for the F508del mutation in the CFTR gene.</p>...
